Duration for carrying SARS-CoV-2 in COVID-19 patients.
作者信息
Du Xinwei, Yu Xue, Li Qingqing, Li Xianyang, Qin Tao, Luo Qiankun, Wang Miaomiao, Jiang Minlin, Bai Li, Wang Xiaoping, Pan Yanfeng
机构信息
Department of Infection, The People's Hospital of Suzhou New District, 95th Huashan road, Suzhou New District, Suzhou, Jiangsu 215129, China; Department of Respiratory Medicine, Shangqiu Municipal Hospital, Intersection of guide south road and yingbin road, Suiyang, Henan province, 476000, China.
Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Rd, Zhengzhou, 450000 China.
出版信息
J Infect. 2020 Jul;81(1):e78-e79. doi: 10.1016/j.jinf.2020.03.053. Epub 2020 Apr 10.
Abstract
摘要
相似文献
1
Duration for carrying SARS-CoV-2 in COVID-19 patients.新冠病毒肺炎患者体内新冠病毒的携带时长。
J Infect. 2020 Jul;81(1):e78-e79. doi: 10.1016/j.jinf.2020.03.053. Epub 2020 Apr 10.
2
Duration of SARS-CoV-2 viral RNA in asymptomatic carriers.无症状携带者中新冠病毒RNA的持续时间。
Crit Care. 2020 May 24;24(1):245. doi: 10.1186/s13054-020-02952-0.
3
Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).无症状冠状病毒感染：中东呼吸综合征冠状病毒和严重急性呼吸综合征冠状病毒2（新型冠状病毒肺炎）
Travel Med Infect Dis. 2020 May-Jun;35:101608. doi: 10.1016/j.tmaid.2020.101608. Epub 2020 Feb 27.
4
From SARS-CoV to SARS-CoV-2: The response and challenge of forensic infectious disease autopsy.从严重急性呼吸综合征冠状病毒到严重急性呼吸综合征冠状病毒2：法医传染病尸检的应对与挑战
Fa Yi Xue Za Zhi. 2020 Feb;36(1):1-3. doi: 10.12116/j.issn.1004-5619.2020.01.001. Epub 2020 Feb 25.
5
A cluster of pneumonia associated with the SARS-Cov-2 outside of Wuhan related to a house-warming banquet.武汉以外与一次乔迁宴相关的新冠肺炎聚集性病例。
J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.034. Epub 2020 Apr 10.
6
Challenges and issues of SARS-CoV-2 pool testing.新型冠状病毒2019（SARS-CoV-2）混合检测的挑战与问题
Lancet Infect Dis. 2020 Nov;20(11):1233-1234. doi: 10.1016/S1473-3099(20)30467-9. Epub 2020 Jul 14.
7
Challenges and issues of SARS-CoV-2 pool testing.新型冠状病毒2019（SARS-CoV-2）混合检测的挑战与问题
Lancet Infect Dis. 2020 Nov;20(11):1233. doi: 10.1016/S1473-3099(20)30463-1. Epub 2020 Jul 14.
8
Challenges and issues of SARS-CoV-2 pool testing.新型冠状病毒2019（SARS-CoV-2）混合检测的挑战与问题
Lancet Infect Dis. 2020 Nov;20(11):1232-1233. doi: 10.1016/S1473-3099(20)30516-8. Epub 2020 Jul 14.
9
Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.伊维菌素，一种治疗新型冠状病毒/新冠肺炎的新候选药物。
Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. doi: 10.1186/s12941-020-00368-w.
10
SARS-CoV, Mers-CoV and COVID-19: what differences from a dermatological viewpoint?严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒与新型冠状病毒肺炎：从皮肤病学角度看有哪些差异？
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e581-e582. doi: 10.1111/jdv.16738. Epub 2020 Jul 2.
引用本文的文献
1
A robust web-based tool to predict viral shedding in patients with Omicron SARS-CoV-2 variants.一种强大的基于网络的工具，用于预测感染奥密克戎SARS-CoV-2变体患者的病毒脱落情况。
ERJ Open Res. 2024 May 20;10(3). doi: 10.1183/23120541.00939-2023. eCollection 2024 May.
2
A mathematical model for the within-host (re)infection dynamics of SARS-CoV-2.一个关于 SARS-CoV-2 宿主内（再）感染动力学的数学模型。
Math Biosci. 2024 May;371:109178. doi: 10.1016/j.mbs.2024.109178. Epub 2024 Mar 13.
3
Association Between Total Cell Free DNA and SARS-CoV-2 In Kidney Transplant Patients: A Preliminary Study.总游离 DNA 与肾移植患者 SARS-CoV-2 之间的关系：一项初步研究。
Transplant Proc. 2022 Jul-Aug;54(6):1446-1454. doi: 10.1016/j.transproceed.2022.02.027. Epub 2022 Mar 15.
4
Persistent Positivity of Reverse Transcriptase-Polymerase Chain Reaction Test among Patients with COVID-19 in Rural Teaching Hospital: A Descriptive Cross-sectional Study.农村教学医院 COVID-19 患者逆转录-聚合酶链反应检测的持续阳性：一项描述性横断面研究。
JNMA J Nepal Med Assoc. 2021 Nov 15;59(243):1136-1140. doi: 10.31729/jnma.7077.
5
Calculating the number of undetected active SARS-CoV-2 infections from results of population-wide antigen tests.从全人群抗原检测结果推算未检出的 SARS-CoV-2 活跃感染数。
J Med Life. 2021 Nov-Dec;14(6):797-801. doi: 10.25122/jml-2021-0243.
6
Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients.SARS-CoV-2 抗体在康复期 COVID-19 患者中的 1 年以上持续时间和年龄差异。
J Med Virol. 2021 Dec;93(12):6506-6511. doi: 10.1002/jmv.27152. Epub 2021 Jul 26.
7
Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus.治疗方案对 SARS-CoV-2 冠状病毒抗体反应的影响。
Front Immunol. 2021 Apr 15;12:580147. doi: 10.3389/fimmu.2021.580147. eCollection 2021.
8
Towards a sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264 studies.面向 SARS-CoV-2 分子检测的敏感且准确解读：264 项研究的快速综述。
Euro Surveill. 2021 Mar;26(10). doi: 10.2807/1560-7917.ES.2021.26.10.2001134.
9
Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital.在一家意大利参考医院收治的大量 COVID-19 患者的上呼吸道标本中，病毒 RNA 持续排出的风险和预测因素。
Int J Infect Dis. 2021 Apr;105:532-539. doi: 10.1016/j.ijid.2021.02.117. Epub 2021 Mar 3.
10
Characteristics and mechanisms to control a COVID-19 outbreak on a leukemia and stem cell transplantation unit.白血病和干细胞移植病房中控制 COVID-19 疫情的特点和机制。
Cancer Med. 2021 Jan;10(1):237-246. doi: 10.1002/cam4.3612. Epub 2020 Dec 12.
本文引用的文献
1
Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.严重急性呼吸综合征冠状病毒 2 再激活的临床特征。
J Infect. 2020 May;80(5):e14-e17. doi: 10.1016/j.jinf.2020.03.001. Epub 2020 Mar 20.
2
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
3
World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).世界卫生组织宣布全球紧急状态：对 2019 年新型冠状病毒（COVID-19）的回顾。
Int J Surg. 2020 Apr;76:71-76. doi: 10.1016/j.ijsu.2020.02.034. Epub 2020 Feb 26.
4
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
5
Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020.2020 年中国浙江省新冠病毒 SARS-CoV-2 的潜在症状前传播。
Emerg Infect Dis. 2020 May;26(5):1052-1054. doi: 10.3201/eid2605.200198. Epub 2020 May 17.
6
Asymptomatic cases in a family cluster with SARS-CoV-2 infection.新型冠状病毒肺炎（SARS-CoV-2）感染家庭聚集性病例中的无症状感染者。
Lancet Infect Dis. 2020 Apr;20(4):410-411. doi: 10.1016/S1473-3099(20)30114-6. Epub 2020 Feb 19.
7
The first 2019 novel coronavirus case in Nepal.尼泊尔首例2019新型冠状病毒病例。
Lancet Infect Dis. 2020 Mar;20(3):279-280. doi: 10.1016/S1473-3099(20)30067-0. Epub 2020 Feb 10.
8
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
9
Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.与甲型流感病毒（H7N9）感染患者病毒持续排出相关的因素。
J Infect Dis. 2018 May 5;217(11):1708-1717. doi: 10.1093/infdis/jiy115.
10
Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome.疑似严重急性呼吸综合征患者中冠状病毒的病毒脱落模式
Lancet. 2004 May 22;363(9422):1699-700. doi: 10.1016/S0140-6736(04)16255-7.
Zotero 插件